How do small life science firms strike major deals with international giants?

The CED is hosting a panel discussion Wednesday to discuss that very topic.

Representatives of four companies involved in two of the largest life science deals involving RTP firms – GSK and Liquidia; Chimerix and Merck – will share insiders’ views about the transactions at the CED Biotech Forum.

Here’s how Tech Wire described the deals:

  • GSK-Liquidia in June:

“Drug giant GlaxoSmithKline is taking an equity stake, providing research funding and paying cash up front for rights to drug candidates being developed by Triangle-based Liquidia Technologies.

“Specific financial terms were not disclosed.

“However, in the announcement, Liquidia noted:

“‘Upfront payment, R&D funding, licensing, and development and regulatory milestone payments under this collaboration could total up to several hundred million dollars upon all contingent payments coming due.'”

  • Merck-Chimerix in July:

“Antiviral therapeutics company Chimerix has licensed rights to its HIV drug candidate to pharmaceutical giant Merck (NYSE: MRK) in a deal that gives Chimerix an up-front payment of $17.5 million.

“RTP-based Chimerix stands to gain up to $151 million more in milestone payments depending on the progress of CMX157. The company would also receive royalties on sales of a successfully commercialized drug. Merck receives exclusive global rights to the compound and takes on the responsibility for developing and commercializing a new HIV drug.”

Speakers include:

  • Kyle Chenet, vice president for corporate development at Liquidia
  • Jennifer Johnson, director of worldwide business development, transactions and investment management, GSK
  • Dr. Sanjeev Munshi, director, External Research and Licensing, Merck
  • Kenneth Moch, CEO, Chimerix

The event takes place at the N.C. Biotechnology Center starting at 5:30 p.m.

  • December CED Events

Tuesday, Dec. 4 – CED Presents: Emerging Trends: Walking the Walk

Tuesday, Dec. 4 – Member-Only Reception at Geomagic

Wednesday, Dec. 5 – CED Biotech Forum: The Anatomy of a Deal

Tuesday, Dec. 11 – CED AfterHours – Durham